Sex-based differences in the effect of digoxin for the treatment of heart failure
- PMID: 12409542
- DOI: 10.1056/NEJMoa021266
Sex-based differences in the effect of digoxin for the treatment of heart failure
Abstract
Background: The Digitalis Investigation Group trial reported that treatment with digoxin did not decrease overall mortality among patients with heart failure and depressed left ventricular systolic function, although it did reduce hospitalizations slightly. Even though the epidemiologic features, causes, and prognosis of heart failure vary between men and women, sex-based differences in the effect of digoxin were not evaluated.
Methods: We conducted a post hoc subgroup analysis to assess whether there were sex-based differences in the effect of digoxin therapy among the 6800 patients in the Digitalis Investigation Group study. The presence of an interaction between sex and digoxin therapy with respect to the primary end point of death from any cause was evaluated with the use of Mantel-Haenszel tests of heterogeneity and a multivariable Cox proportional-hazards model, adjusted for demographic and clinical variables.
Results: There was an absolute difference of 5.8 percent (95 percent confidence interval, 0.5 to 11.1) between men and women in the effect of digoxin on the rate of death from any cause (P=0.034 for the interaction). Specifically, women who were randomly assigned to digoxin had a higher rate of death than women who were randomly assigned to placebo (33.1 percent vs. 28.9 percent; absolute difference, 4.2 percent, 95 percent confidence interval, -0.5 to 8.8). In contrast, the rate of death was similar among men randomly assigned to digoxin and men randomly assigned to placebo (35.2 percent vs. 36.9 percent; absolute difference, -1.6 percent; 95 percent confidence interval, -4.2 to 1.0). In the multivariable analysis, digoxin was associated with a significantly higher risk of death among women (adjusted hazard ratio for the comparison with placebo, 1.23; 95 percent confidence interval, 1.02 to 1.47), but it had no significant effect among men (adjusted hazard ratio, 0.93; 95 percent confidence interval, 0.85 to 1.02; P=0.014 for the interaction).
Conclusions: The effect of digoxin therapy differs between men and women. Digoxin therapy is associated with an increased risk of death from any cause among women, but not men, with heart failure and depressed left ventricular systolic function.
Copyright 2002 Massachusetts Medical Society
Comment in
-
Digoxin--new perspective on an old drug.N Engl J Med. 2002 Oct 31;347(18):1394-5. doi: 10.1056/NEJMp020118. N Engl J Med. 2002. PMID: 12409540 No abstract available.
-
Digoxin for the treatment of heart failure.N Engl J Med. 2003 Feb 13;348(7):661-3; author reply 661-3. doi: 10.1056/NEJM200302133480718. N Engl J Med. 2003. PMID: 12584380 No abstract available.
-
Digoxin increases mortality among women with congestive heart failure.J Fam Pract. 2003 Feb;52(2):106, 111. J Fam Pract. 2003. PMID: 12585985
-
Digoxin for the treatment of heart failure.N Engl J Med. 2003 Feb 13;348(7):661-3; author reply 661-3. N Engl J Med. 2003. PMID: 12587574 No abstract available.
-
Digoxin for the treatment of heart failure.N Engl J Med. 2003 Feb 13;348(7):661-3; author reply 661-3. N Engl J Med. 2003. PMID: 12587575 No abstract available.
-
Digoxin increased risk of death in women, but not men, with heart failure.Evid Based Nurs. 2003 Jul;6(3):80. doi: 10.1136/ebn.6.3.80. Evid Based Nurs. 2003. PMID: 12882193 No abstract available.
Similar articles
-
Relationship of serum digoxin concentration to mortality and morbidity in women in the digitalis investigation group trial: a retrospective analysis.J Am Coll Cardiol. 2005 Aug 2;46(3):497-504. doi: 10.1016/j.jacc.2005.02.091. J Am Coll Cardiol. 2005. PMID: 16053964
-
The effect of digoxin on mortality and morbidity in patients with heart failure.N Engl J Med. 1997 Feb 20;336(8):525-33. doi: 10.1056/NEJM199702203360801. N Engl J Med. 1997. PMID: 9036306 Clinical Trial.
-
Renal function, digoxin therapy, and heart failure outcomes: evidence from the digoxin intervention group trial.J Am Soc Nephrol. 2004 Aug;15(8):2195-203. doi: 10.1097/01.ASN.0000135121.81744.75. J Am Soc Nephrol. 2004. PMID: 15284305 Clinical Trial.
-
[New aspects in clinical cardiology: sex-based differences in cardiovascular morbidity and mortality].Cas Lek Cesk. 2003;142(4):195-6. Cas Lek Cesk. 2003. PMID: 12841118 Review. Czech.
-
Update on digoxin therapy in congestive heart failure.Am Fam Physician. 2000 Jul 15;62(2):409-16. Am Fam Physician. 2000. PMID: 10929703 Review.
Cited by
-
The effects of digoxin on heart failure mortality and re-admission in a single center cross-sectional study.J Cardiovasc Thorac Res. 2024;16(3):194-197. doi: 10.34172/jcvtr.33062. Epub 2024 Sep 20. J Cardiovasc Thorac Res. 2024. PMID: 39430283 Free PMC article.
-
How to make cardiology clinical trials more inclusive.Nat Med. 2024 Oct;30(10):2745-2755. doi: 10.1038/s41591-024-03273-3. Epub 2024 Oct 14. Nat Med. 2024. PMID: 39402268 Review.
-
"Cardiac glycosides"-quo vaditis?-past, present, and future?Naunyn Schmiedebergs Arch Pharmacol. 2024 Jul 15. doi: 10.1007/s00210-024-03285-3. Online ahead of print. Naunyn Schmiedebergs Arch Pharmacol. 2024. PMID: 39007928 Review.
-
A Systematic Review of Sex-Specific Reporting in Heart Failure Clinical Trials: Trial Flow and Results.JACC Adv. 2022 Sep 21;1(4):100079. doi: 10.1016/j.jacadv.2022.100079. eCollection 2022 Oct. JACC Adv. 2022. PMID: 38939721 Free PMC article.
-
Sex in cardiovascular disease: Why this biological variable should be considered in in vitro models.Sci Adv. 2024 May 10;10(19):eadn3510. doi: 10.1126/sciadv.adn3510. Epub 2024 May 10. Sci Adv. 2024. PMID: 38728407 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical